New

Brainomix

The AI engine Fit Assessment

Beta

The company develops AI-powered imaging biomarkers and software for healthcare applications, enabling AI-driven stroke imaging and ILD/cancer diagnostics to improve patient care.

Blurb

Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions

HQ Location

Oxford (United Kingdom)

Founded

2010

Employees

51 - 200

Total funding raised

$60.19M

Funding Status

Series C, $6.48M, February 24, 2026

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere.



Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time.



Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.



Reach out today to learn why Brainomix is essential for you, your patients, and your stroke pathway.